• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics, Roche expand distribution deal for Eversense glucose monitor

December 2, 2016 By Sarah Faulkner

Senseonics, Roche expand distribution deal for glucose monitorSenseonics (NYSE:SENS) said today that it expanded its exclusive distribution agreement with Roche (PINK:RHHBY) for its implantable continuous glucose monitoring system for people with diabetes. The new agreement includes all of Europe, the Middle East and Africa, excluding Scandinavia, Finland and Israel.

According to the agreement, Germantown, Maryland-based Senseonics has given Roche exclusive rights to promote, market and sell the Eversense system in specified territories. Senseonics will still be responsible for product development, regulatory approval, quality management and manufacturing, while Roche will take over commercializing the system.

The expansion builds upon an agreement signed by the 2 companies in May this year for distribution of Senseonic’s system in Germany, Italy and the Netherlands.

The Eversense continuous glucose monitor is designed to last up to 90 days. The implanted glucose sensor and wearable smart transmitter work with a mobile application to enable real-time monitoring of blood glucose levels. Senseonics submitted a premarket approval application to the FDA this September, after the system won the CE Mark in the European Union in May.

“The partnership we formed with Roche earlier this year is off to a promising start. The early success and experience that each of our teams are gaining drove the mutual decision to expand our relationship,” Senseonics president & CEO Tim Goodnow said in prepared remarks. “We are excited to add these additional countries and look forward to growing the presence of Eversense through this partnership.”

Filed Under: Diabetes, Distribution, Featured, Wall Street Beat Tagged With: Roche, Senseonics

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS